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Abstract
Background: The effect of multiple micronutrient supplementation on vitamin B12 and folate has hither to not
been reported in African HIV infected children. This paper describes vitamin B12 and folate status of Ugandan HIV
infected children aged 1-5 years and reports the effect of multiple micronutrient supplementation on serum
vitamin B12 and folate concentrations.
Methods: Of 847 children who participated in a multiple micronutrient supplementation trial, 214 were assessed
for vitamin B12 and folate concentrations pre and post supplementation. One hundred and four children were
randomised to two times the recommended dietary allowance (RDA) of a 14 multiple micronutrient supplement
(MMS) and 114 to a ‘standard of care’ supplement of 6 multivitamins (MV). Serum vitamin B12 was measured by an
electrochemiluminescence immunoassay and folate by a competitive protein-binding assay using Modular E
(Roche) automatic analyzer. Vitamin B12 concentrations were considered low if less than 221picomoles per litre
(pmol/L) and folate if < 13.4 nanomoles per litre (nmol/L). The Wilcoxon Signed Ranks test was used to measure
the difference between pre and post supplementation concentrations.
Results: Vitamin B12 was low in 60/214 (28%) and folate in 62/214 (29.0%) children. In the MMS group, the median
concentration (IQR) of vitamin B12 at 6 months was 401.5 (264.3 - 518.8) pmol/L compared to the baseline of 285.5
(216.5 - 371.8) pmol/L, p < 0.001. The median (IQR) folate concentrations increased from 17.3 (13.5 - 26.6) nmol/L
to 27.7 (21.1 - 33.4) nmol/L, p < 0.001. In the ‘standard of care’ MV supplemented group, the median concentration
(IQR) of vitamin B12 at 6 months was 288.5 (198.8 - 391.0) pmol/L compared to the baseline of 280.0 (211.5 - 386.3)
pmol/L while the median (IQR) folate concentrations at 6 months were 16.5 (11.7 - 22.1) nmol/L compared to 15.7
(11.9 - 22.1) nmol/L at baseline. There was a significant difference in the MMS group in both vitamin B12 and folate
concentrations but no difference in the MV group.
Conclusions: Almost a third of the HIV infected Ugandan children aged 1-5 years had low serum concentrations
of vitamin B12 and folate. Multiple micronutrient supplementation compared to the ‘standard of care’ supplement
of 6 multivitamins improved the vitamin B12 and folate status of HIV infected children in Uganda.
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Background
Vitamin B12 and folate deficiency are relatively common
in low income countries compared to high income
countries, particularly in communities where the diet is
predominantly vegetarian [1-4], where major sources of
vitamin B12 such as meat, fish, poultry, milk and forti-
fied breakfast cereals [5] are consumed in small amounts
or are not readily available. Dietary sources of folate, on
the other hand, are more prevalent as they include
green leafy vegetables, fruits and dried beans and peas
[6]. During infancy and childhood folate and vitamin
B12 deficiency have been associated with failure to
thrive, reduced physical activity and cognitive function
and megaloblastic anaemia [7,8]. However many of the
symptoms are non-specific and may result from a vari-
ety of medical conditions.
A significant number of HIV-infected children in low-
income countries remain at risk of increased morbidity
due to immunodeficiency related to HIV infection in
addition to micronutrient deficiencies. Low vitamin B12
status has been associated with poor immunological sta-
tus and HIV disease progression in adults [9]. In follow
up studies of HIV infected pregnant women micronutri-
ent supplementation resulted in improved child growth,
haematological indices and vitamin B12 levels [10].
Food supplementation and multiple micronutrient for-
tification of foods and beverages in children with
unknown HIV status living in low income countries
have shown improved haemoglobin levels and concen-
trations of deficient micronutrients [2,11-14].
We hypothesised that supplementation with two
recommended dietary allowances (RDA) of 14 multiple
micronutrients (MMS) would increase serum vitamin
B12 and folate concentrations compared to a 1 RDA of 6
multivitamin (MV) ‘standard of care’ supplement. We
here report the baseline vitamin B12 and folate status in
Ugandan HIV infected children aged 1-5 years and the
effect of multiple micronutrient supplementation on
serum concentrations of vitamin B12 and folate.
Methods
Design
The study was a randomised controlled trial conducted
between 2005 and 2008 at 7 paediatric HIV clinics in
Uganda. Participants were allocated to the intervention
or ‘standard of care’ supplement in a 1:1 ratio.
Participants
HIV infected children aged 1- 5 years presenting at the
study clinics for follow up visits were eligible for the
trial. Children who had enrolled in other studies or
were unable to adhere to a regular follow up schedule
and those whose mothers or guardians declined consent
were excluded. There were no other micronutrient
supplementation studies going on at the time so the
exclusion for those who were participating in other stu-
dies was done to avoid participant fatigue and interfer-
ence with procedures. Multivitamin supplementation
was routinely practiced at the study clinics but this was
not an exclusion criteria. Eligible participants were con-
secutively enrolled, assigned to the study intervention or
‘standard of care’ supplement and followed for one year.
The study sites have been previously described [15].
Three sites were located in the capital city of Uganda
(Kampala) and these were Mulago (the national referral
hospital), Mildmay Centre and Nsambya hospital. The
other sites were situated in the regional hospitals in the
east, south-west, central and north of the country. For
logistical reasons, transport and storage, it was not pos-
sible to collect samples for biochemical tests from all
the sites. Therefore blood samples for biochemical tests
were only collected from the three Kampala sites. The
samples were subsequently shipped to the clinical chem-
istry laboratory at Haukeland University Hospital, Ber-
gen (Norway), where vitamin B12 and folate were
analysed.
The trial enrolled 847 children at all the seven study
sites. Out of 705 children from whom blood samples
could be stored for micronutrient tests, 261 had no suf-
ficient samples, 230 had other micronutrient tests done
or had either baseline but no result at the second sam-
pling. Because of multiple analyses 214 children had
both baseline and 6 months results for vitamin B12 and
folate concentrations. There were no significant differ-
ences in demographic and clinical characteristics such
as age, sex, anthropometric measurements and other
laboratory measurements like CD4 + cell count among
those who had results for vitamin B12 and folate com-
pared to those who did not.
The study was approved by the College of Health
Sciences Research and Ethics Committee, Makerere
University, Kampala, Uganda; the Uganda National
Council for Science and Technology, and the Regional
Committee for Medical Research Ethics, Western
Norway.
Cotrimoxazole prophylaxis, initiation of ART, manage-
ment of common illnesses and opportunistic infections
was offered using the national guidelines for Paediatric
HIV care.
Intervention
The trial supplements were manufactured in powder
form and packaged by NUTRISET, France using a for-
mula that was determined by the investigators based on
twice the recommended dietary intake for a 4 year old
category [6]. We decided to use 2 RDA based on the
fact that many children were malnourished despite rou-
tine supplementation with multivitamins. Secondly some
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previous studies of HIV infected adults had indicated
that HIV infected persons may require multiples of
RDA in order to achieve normal serum concentrations
of micronutrients. Thirdly, looking at the tables of the
nutritional requirements for children [6] we noted that
there are 2 age bands where our participants belonged,
1-3 and 4-8 years of age. We noticed that there were
minor variations in dosages of some micronutrients
while others like iodine and vitamin D did not vary. We
therefore decided to use the 4 year old category for our
study. In addition it was easier to administer a uniform
intervention. There were no similar studies in the region
and there was no literature to guide us on the micronu-
trient status of Ugandan HIV infected children. Also
there were no food composition tables based on the
local foods so we could not estimate how much micro-
nutrients children get from the usual diet. The MMS
comprised of 800 mcg vitamin A, 1.2 mg vitamin B1, 1.2
mg vitamin B2, 16 mg niacin, 1.2 mg vitamin B6, 2.4
mcg vitamin B12, 50 mg vitamin C, 400 IU vitamin D,
14 mg vitamin E, 40 mcg folate, 60 mcg selenium, 10
mg zinc, 800 mcg copper and 180 mcg iodine. The mul-
tivitamin ‘standard of care’ supplement contained 400
mcg vitamin A, 0.6 mg vitamin B1, 0.6 mg vitamin B2, 8
mg niacin, 25 mg vitamin C and 200 IU vitamin D. The
contents and formula for the MV supplement was based
on the regular multivitamins supplied at the study
clinics as routine care of HIV infected children. The
daily dose was 4 g and this was equivalent to a levelled
scoop supplied by the manufacturer. The powder was
mixed with 10 to 20 ml of milk or water. The first dose
of the supplement was administered at the study clinic
following a demonstration and under observation by the
study nurse. At the time of administering the first dose
we counselled the mother on the importance of com-
pleting the dose and ensuring that the daily dose was
given. Whenever the child vomited during or within 30
minutes of administering the dose a repeat dose was
given. Mothers were given calendar charts and
instructed to tick on the appropriate date whenever a
dose was given. They would return to the clinic with
the container/remaining supplement together with the
calendar charts on routine follow up visits. The remain-
ing amount of supplement was measured using a light
weight scale and the level of compliance determined
using the proportion of the supplement consumed
against the expected. The supply for one month was
140 grams and the expected dose for 30 days was 120
grams. The remaining 20 grams was to cater for vom-
ited doses or in case there was spillage. The mothers
administered the subsequent doses from home and it
was not possible to observe them. The supplements
were given for a period of 6 months when the second
sample of blood was drawn.
Outcomes
The outcome measures were serum vitamin B12 and
folate concentrations pre and post supplementation and
factors associated with low concentrations at baseline.
These were secondary objectives of the trial. Survival
was assessed as the primary objective whose findings
have been previously reported [15].
Randomisation and blinding
The randomisation sequence was generated using the
stata soft ware in variable blocks of 4 to 20. The supple-
ments were manufactured and packaged in 140 g plastic
containers which were sequentially numbered. RB gen-
erated the randomisation sequence at Geneva and sent
it to the manufacturers in France. The randomisation
code was kept at Geneva and by the manufacturers. The
treatment assignment was revealed upon completion of
the study.
Participants were enrolled by the principal investigator
and the other study doctors. The trial nurse at the study
sites dispensed the supplement in serial order. The col-
our, consistency and odour of the intervention and
‘standard of care’ supplement were similar. The princi-
pal investigator, study personnel including doctors and
nurses and the caretakers/participants were all blinded
to treatment assignment.
Clinical and laboratory measurements
At enrolment demographic information, history of the
child’s illness and findings on physical examination
were recorded. Non fasting blood samples were drawn
for CD4+ cell count and micronutrient analysis using
procedures previously described in the same cohort
[15]. Vitamin B12 was measured by electrochemilumi-
nescence immunoassay, and folate by a competitive pro-
tein-binding assay on Modular E (Roche) automatic
analyzer. The coefficient of variation for the assays was
less than 5%. To determine cut off values for low vita-
min B12 and folate, we considered what other research-
ers have used since there were no reference values for
Ugandan children. Vitamin B12 concentrations were
considered low if less than 221 picomoles per litre
(pmol/L), combining both very low (<148 pmol/L) and
marginal (148 - 221 pmol/L) status. Concentrations
equal or > 221 pmol/L was considered to be normal.
Folate concentrations were low if < 13.4 nanomoles per
litre (nmol/L), similarly combining both very low (<6.8
nmol/L) and marginal (6.8 - 13.4 nmol/L) status. Con-
centrations ≥ 13.4 nmol/L were regarded as being nor-
mal [16,17].
Statistical analysis
Change in micronutrient concentrations of each partici-
pant was computed in SPSS as follows: concentration at
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6 months minus concentration at baseline. Medians and
their interquartile ranges were used for summarising the
data. Because vitamin B12 and folate concentrations
were not normally distributed the Wilcoxon Signed
Ranks test was used to measure the difference between
baseline and 6 months in each group. Differences in
categorical variables were tested with the Pearson chi-
square or Fischer’s exact test. Differences were consid-
ered significant if a two-sided p-value was less than
0.05. Multiple regression analysis was performed to
examine factors associated with low vitamin B12 or
folate concentrations at baseline assessment.
Results
Baseline characteristics of participants
Of the 214 children with both baseline and 6 months
results for vitamin B12 and folate, 104 (48.6%) received
MMS while the rest received the ‘standard of care’ MV
supplement. The distribution of children by arm and
strata is presented in figure 1. Males and females were
equally represented. The median age (IQR) was 33.2
months (19.6 - 44.4) in the MMS and 30.3 (19.8 - 45.5)
in the MV group. Baseline characteristics are described
in table 1. There were no significant differences between
the two treatment groups.
Overall, 60 children (28.0%) had low vitamin B12 con-
centrations less than 221.0 pmol/L, and 62 (29.0%) had
low folate concentrations less than 13.4 nmol/L. Among
the children with low vitamin B12 status, 13 (6.0%) had
very low and 47 (22.0%) marginal concentrations (148 -
221 pmol/L). Of the 62 children with low folate status,
3 (1.4%) had very low (<6.8 nmol/L) and 59 (27.6%) had
marginal concentrations (6.8 - 13.4 nmol/L).
Comparisons between baseline and 6 months’ vitamin
B12 and folate concentrations
Baseline median serum vitamin B12 and folate concen-
trations were similar in the two groups. Following sup-
plementation with multiple micronutrients (MMS)
vitamin B12 concentrations increased from a median
(IQR) of 285.5 (216.5 - 371.8) to 401.5 (264.3 - 518.8)
pmol/L at 6 months. This difference was statistically sig-
nificant (p < 0.001). Similarly folate concentrations
increased from 17.3 (13.5 - 26.6) to 27.7 (21.1 - 33.4)
nmol/L and this difference was also significant, p <
0.001 (Table 2). There was no significant difference in
the MV ‘standard of care’ group.
Of the 44 children who were on HAART, 19 received
MMS while 25 received MV. In this stratum the median
(IQR) concentration of vitamin B12 in the MMS arm at
baseline was 262.0 (215.0 - 342.0) compared to 453.0
(261.0 - 594.0) pmol/L at 6 months, p = 0.002. The
median (IQR) folate concentrations increased from 18.6
(13.8 - 23.9) to 25.0 (21.3 - 32.9) nmol/L, p = 0.040.
Although the numbers were small these were significant
differences. There was no significant difference in the
MV group. Median (IQR) baseline vitamin B12 concen-
trations were higher in the HAART stratum [306.5
847 children enrolled
110 in the
‘standard of care’ arm
104 in the
multiple micronutrient arm
85 HAART 
naïve
19 HAART 
stratum
214 paired samples
for vitamin B12 and folate
142 at rural sites
261no/minimal samples
230 0ther micronutrient 
tests
25 HAART 
stratum
85 HAART 
naïve
Figure 1 Study profile.
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(209.3 - 372.8) pmol/L] compared to the non-HAART
stratum [280.0 (218.0 - 386.3) pmol/L], but not signifi-
cantly so. Folate concentrations were almost the same
[16.1 (13.5 - 22.0) nmol/L] in the HAART and [16.0
(12.1 - 24.9) nmol/L] non-HAART stratum. Thirteen
out of 40 children (32.5%) who were on HAART had
CD4+ cell percent < 25 compared to 100/159 (63.5%)
who were HAART naïve, p = 0.001 (Fisher’s exact test).
Median (IQR) duration of anti-retroviral therapy was 9
(6.0 - 14.3) months.
Table 1 Characteristics of 214 Ugandan HIV infected children analysed for vitamin B12 and folate by intervention
group
Number (N) MMS n (%) ’Standard of care’ MV n (%) p-value
Sex: Male 100 49 (49.0) 51 (51.0) >0.99
Age less than 24 months 70 33 (47.1) 37 (52.9) 0.77
Mother as carer 146 73 (50.0) 73 (50.0) 0.56
On HAART 44 19 (43.2) 25 (56.8) 0.50
Routine CTX 193 93 (48.2) 100 (51.8) 0.82
Routine MV 144 68 (47.2) 76 (52.8) 0.66
WHZ < -2 28 14 (50.0) 14 (50.0) >0.99
HAZ < -2 113 56 (49.6) 57 (50.4) 0.89
WHO stage 3 or 4 56 26 (46.4) 30 (53.6) 0.76
CD4+ T cells < 25% 114 50 (43.9) 64 (56.1) 0.20
Elevated CRP (> 6 g/dl) 67 33 (49.3) 34 (50.7) 0.42
Low haemoglobin (< 11 g/dl) 127 61 (48.0) 66 (52.0) 0.89
Low vitamin B12 (< 221 pmol/L) 60 29 (48.3) 31 (51.7) 0.96
Low folate (< 13.4 nmol/L) 62 25 (40.3) 37 (59.7) 0.13
MMS = multiple micronutrient supplementation
HAART = Highly active anti-retroviral therapy
CTX = Cotrimoxazole
MV = ‘standard of care’ multivitamins
WHZ = Weight for height z-score
HAZ = Height for age z-score
WHO = World Health Organisation
CD4+ = Cluster of differentiation 4
CRP = C-reactive protein
Table 2 Biochemical and haematological measurements at baseline and at 6 months of supplementation by
intervention group
Multiple Micronutrient Supplementation
group (n = 104)
Comparative ‘standard of care’ multivitamins
group (n = 110)
Measurement Median (IQR) P-value Median (IQR) p-value
Vitamin B12 (pmol/L)
Baseline 285.5 (216.5 - 371.8) <0.001 280.0 (211.5 - 386.3) 0.78
6 months 401.5 (264.3 - 518.8) 288.5 (198.8 - 391.0)
Change 90.5 (-0.8 - 203.5) 10.0 (-73.8 - 83.8)
Folate (nmol/L)
Baseline 17.3 (13.5 - 26.6) <0.001 15.7 (11.9 - 22.1) 0.44
6 months 27.7 (21.1 - 33.4) 16.5 (11.7 - 22.1)
Change 8.0 (-0.3 - 17.1) -0.6 (-3.5 - 5.8)
Haemoglobin (g/dl)
Baseline 10.0 (8.7 - 11.2) 0.04 9.8 (8.8 - 11.2) <0.001
6 months 10.9 (9.4 - 11.7) 10.6 (9.6 - 11.7)
Change 0.3 (-0.4 - 0.9) 0.6 (-0.2 - 1.4)
CD4+ count (cells/μL)
Baseline 1201 (822 - 1556) 0.16 1033 (728 - 1406) 0.52
6 months 1039 (725 - 1358) 1043 (704 - 1484)
Change -137 (-348 - 254) 35 (-278 - 352)
Wilcoxon Signed Ranks test was used to measure the difference between baseline and 6 months.
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Vitamin B12 and folate status at 6 months of
supplementation
Overall, 42 (19.6%) children had low concentrations of
vitamin B12 at 6 months, 9 (4.2%) with very low and 33
(15.4%) with marginal concentrations. Nine children
(1.4%) were in the MMS and 33 (78.6%) in the MV
group. This was a statistically significant difference. The
odds ratio was 4.5 (95% CI; 2.0 - 10.0). Folate concen-
trations were low in 44/214 (20.6%) children at 6
months of follow up; almost all of them had marginal
concentrations. Five children (11.4%) were supplemen-
ted with MMS and 39 (88.6%) MV; Odds ratio 10.8
(95% CI; 4.1 - 28.9). Low vitamin B12 and folate concen-
trations were more frequent in the MV supplemented
group.
Other clinical and haematological findings
Eight of the 214 children had signs of neurological dis-
ease, 6 with delayed or loss of developmental milestones,
3 of whom had low or marginal vitamin B12 status.
There was a significant increase in the haemoglobin sta-
tus in both groups as shown in table 2. There was no
significant change in the CD4 cell counts in either the
MMS or MV group.
HAART strata and initiation of HAART during the study
Of the 44 children on HAART at enrolment, 15 (34.1%)
and 10 (22.7%) had low vitamin B12 and low folate con-
centrations, respectively. The prevalence of low micro-
nutrient status of these two was not significantly
different between the HAART and non-HAART treated
children. Of the 170 HAART naïve children, 21 started
HAART during the study; 13 in MMS and 8 in MV
group. This difference was not significant, p = 0.35.
Seven of the 21 children who initiated HAART during
the study had low vitamin B12 concentrations at
enrolment.
Factors associated with low vitamin B12 or folate
concentrations
Vitamin B12 status was not closely associated with most
of the baseline characteristics (Table 3). However being
male, age less than 24 months and a haemoglobin < 11
g/dl were associated with low folate concentrations. At
multivariate analysis only age and the male sex
remained significantly associated with low serum folate
concentrations.
Discussion
This paper describes the vitamin B12 and folate concen-
trations of HIV-infected Ugandan children aged 1-5
years and the effect of 2RDA of 14 multiple micronutri-
ents that contained vitamin B12 and folate versus the
‘standard of care’ multivitamins in 1RDA without
vitamin B12 and folate. Almost a third of the children
had low vitamin B12 and low folate concentrations at
baseline. Very low serum concentrations were uncom-
mon. MMS containing vitamin B12 and folate improved
both vitamin B12 and folate concentrations compared to
the ‘standard of care’ multivitamins.
Vitamin B12 and folate concentrations in our study are
comparable or slightly lower than what has been
reported in children living in other low-income coun-
tries [1,2,4,17]. Our findings are also comparable to
what other studies in HIV infected adults reported
before the HAART era. These studies showed that low
vitamin B12 concentrations were relatively common with
a prevalence ranging between 10 and 35% [18-22].
There are few studies that have examined vitamin B12
and folate in HIV infected children in Africa. The preva-
lence of low vitamin B12 concentrations in our study was
much higher than the prevalence of 5% reported in South
African HIV infected children [23]. Contrary to our find-
ings a study of HIV infected children in New York showed
elevated vitamin B12 and folate status [24]. Our study
included younger children, the majority of whom were
symptomatic and not on HAART compared to the New
York study. In our study the lack of differences between
the HAART and non-HAART stratum in baseline vitamin
B12 or folate concentrations could be explained by the
short duration of HAART compared to other studies.
Twice the recommended dietary allowance of multiple
micronutrients improved vitamin B12 and folate status
compared to the ‘standard of care’. This is not surpris-
ing since the standard of care supplement did not con-
tain vitamin B12 and folate. This implies that the
standard of care multivitamin is not enough and many
more micronutrients may be required to correct micro-
nutrient deficiencies. A significant number of children
still had low concentrations of vitamin B12 and folate at
the end of 6 months, implying that the duration of sup-
plementation needed to be extended.
Low vitamin B12 could be related to folate deficiency
or to low vitamin B12 binding proteins. Although we did
not find an association between low vitamin B12 and
white blood cell count this does exclude the possibility
that low vitamin B12 concentrations could be related to
neutropenia.
We observed that there was an association between
low folate concentrations and low haemoglobin which
indicates that the anaemia could partly be attributed to
low folate concentrations. In both treatment groups the
haemoglobin improved compared to baseline levels. We
could not conclusively attribute the anaemia to low
folate concentrations since we did not measure red
blood cell folate concentrations. Measuring both serum
folate and Red cell folate would have yielded more diag-
nostic information of folate deficiency. However sub-
Ndeezi et al. Nutrition Journal 2011, 10:56
http://www.nutritionj.com/content/10/1/56
Page 6 of 9
normal serum folate is a useful indicator of folate status
that warrants reporting. In a landscape of multiple defi-
ciencies, such as HIV-infected children in a low-income
country, there is always the potential for other deficien-
cies to alter the response, for instance, iron deficiency
(the supplement did not contain iron). Folate deficiency
has been reported in almost one in two anaemic HIV
infected patients [25]. Other authors have reported asso-
ciations between anaemia, gender and folate deficiency
in children whose HIV infection status was not known
[26].
Neither MMS nor the ‘standard of care’ MV improved
the immunological status of the study children. In fact
there was a slight deterioration in the CD4+ cell counts
among the HAART naïve MMS group. This was contrary
to findings of a trial in HAART treated HIV infected
adults living in the USA where multiple micronutrient
supplementation was associated with improved CD4+
cell count compared to a placebo [27]. The lack of effect
on CD4+ cell count in our study could be explained by
the natural immunological deterioration or it may be
apparent due to the small numbers in the HAART
group. It is also possible that the supplementation was
not long enough to show an impact on CD4+ cell count
since one in five children still had low vitamin B12 and
folate concentrations at 6 months of follow up.
Table 3 Factors associated with low vitamin B12 and folate among HIV infected children in Uganda
Baseline characteristics Number N Low vitamin B12 status
a n (%) Un adjusted OR (95% CI) Adjusted OR (95%CI)
Vitamin B12 status
Age < 24 months 70 19 (27.1) 0.9 (0.6 - 1.5)
Age ≥ 24 months 144 41 (28.5)
Male 100 33 (33.0) 1.4 (0.9 - 2.1) 1.6 (0.8 - 3.1)
Female 114 27 (23.7)
Weight for height z score < -2 28 7 (25.0) 0.9 (0.4 - 1.7)
Weight for height z score ≥ -2 182 52 (28.6)
Haemoglobin < 11 g/dl 127 37 (29.1) 1.1 (0.7 - 1.7)
Haemoglobin ≥ 11 g/dl 87 23 (26.4)
CD4+ < 25% 114 33 (28.9) 1.1 (0.6 - 2.1)
CD4+ ≥ 25% 85 23 (27.1)
On HAART 44 15 (34.1) 1.3 (0.8 - 2.1)
HAART naïve 170 45 (26.5)
Routine CTX prophylaxis 193 56 (29.0) 1.5 (0.6 - 3.8)
No routine CTX prophylaxis 21 4 (19.0)
Previous routine multivitamins 144 40 (27.8) 1.0 (0.6 - 1.5)
No routine multivitamins 70 20 (28.6)
Folate status Low folate
Age < 24 months 70 27 (38.6) 1.6 (1.1 - 2.4) 2.2 (1.1 - 4.5)
Age ≥ 24 months 144 35 (24.3)
Male 100 36 (36.0) 1.6 (1.0 - 2.4) 2.1 (1.1 - 4.0)
Female 114 26 (22.8)
Weight for height z score < -2 28 7 (25.0) 0.8 (0.4 - 1.7)
Weight for height z score ≥ -2 182 54 (29.7)
Haemoglobin < 11 g/dl 127 45 (35.4) 1.8 (1.1 - 2.9) 1.9 (0.9 - 4.6)
Haemoglobin ≥ 11 g/dl 87 17 (19.5)
CD4+ < 25% 114 36 (31.6) 1.2 (0.7 - 1.9)
CD4+ ≥ 25% 85 22 (25.9)
On HAART 44 10 (22.7) 0.7 (0.4 - 1.3)
HAART naïve 170 52 (30.6)
Routine CTX prophylaxis 193 58 (30.1) 1.6 (0.6 - 3.9)
No routine CTX prophylaxis 21 4 (19.0)
Previous routine multivitamins 144 44 (30.6) 1.2 (0.7 - 1.9)
No routine multivitamins 70 18 (25.7)
aLow vitamin B12 < 221 pmol/L,
Low folate < 13.4 nmol/L
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In our setting it is possible that low concentrations of
vitamin B12 and folate may be related to consumption
of marginal or low levels of vitamin B12 and folate since
twice the recommended dietary intakes increased serum
concentrations as opposed to the multivitamin supple-
ment which did not contain vitamin B12 or folate. Some
authors have shown that Vitamin B12 deficiency is rare
in HIV infected persons consuming vitamin B12 well
above the recommended nutrient intakes [28]. In
Uganda one third of children aged between 6 and 24
months are likely to be getting diary products in their
diet and very few are likely to be getting other animal
source foods [29].
We are not certain whether our findings are similar to
children in the general population since we had no con-
trol group of HIV uninfected children. A study of both
HIV-infected and exposed uninfected children in Brazil
showed no differences in micronutrient status [30].
However another study indicated that HIV infected chil-
dren had significantly lower folate levels than the refer-
ence children while vitamin B12 was similar [31].
We were unable to measure serum homocysteine and
methyl malonic acid concentrations which are more reli-
able indicators of vitamin B12 deficiency because of the
limited amount of blood that we could draw from the
children as we had multiple micronutrients to test for.
We also did not conduct absorption studies to examine
the impact of malabsorption on baseline micronutrient
and post-supplementation status. This paper does not
describe the dietary habits of the study children and
whether they had an impact on the outcome.
Conclusion
Low vitamin B12 and folate concentrations are common
in Ugandan HIV infected children aged 1-5 years. Twice
the recommended dietary allowance of 14 multiple
micronutrients as opposed to the 6 multivitamin ‘stan-
dard of care’ supplement improved the vitamin B12 and
folate status of HIV-infected children in Uganda.
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